FrancophonIA/ELRC3.0 huggingface dataset:
English: Dry mouth, which has been observed with medicines like Eklira Genuair, may after using your medicine for a long time, be associated with tooth decay.
Croatian: Suha usta, zabilježena uz lijekove poput Eklira Genuair mogu nakon dugotrajnog uzimanja lijeka biti povezani sa zubnim karijesom.
English: The Eklira Genuair group showed a statistically significant delay in the time to first moderate or severe exacerbation while on-treatment compared to the placebo group.
Croatian: U skupini liječenoj lijekom Eklira Genuair zabilježeno je statistički značajno dulje vrijeme do prve umjerene ili teške egzacerbacije tijekom liječenja u odnosu na skupinu koja je primala placebo.
English: - The other ingredient is lactose monohydrate (refer to Section 2 “Eklira Genuair contains lactose”).
Croatian: - Pomoćna tvar je laktoza hidrat. (pogledajte dio 2. „Eklira Genuair sadrži laktozu“)
English: It is unknown whether aclidinium bromide/metabolites are excreted in human milk.
Croatian: Nije poznato izlučuju li se aklidinijev bromid/metaboliti u majčino mlijeko u ljudi.
English: Patients treated with Eklira Genuair required less rescue medication than patients treated with placebo (a reduction of 0.95 puffs per day at 6 months [p=0.005]).
Croatian: Bolesnici liječeni Eklira Genuairom trebali su manje lijeka za brzo ublažavanje simptoma od bolesnika liječenih placebom (smanjenje od 0,95 potisaka dnevno nakon 6 mjeseci [p=0,005]).
English: What Eklira Genuair is
Croatian: Što je Eklira Genuair
English: Talk to your doctor, pharmacist or nurse before using Eklira Genuair: - if you have had heart problems recently.
Croatian: Obratite se svom liječniku, ljekarniku ili medicinskoj sestri prije nego primijenite Eklira Genuair.
English: Eklira Genuair did not increase the MACE risk in patients with COPD compared to placebo when added to current background therapy (hazard ratio (HR) 0.89; 95% CI: 0.64, 1.23).
Croatian: Eklira Genuair nije povećao rizik od MACE događaja u bolesnika s KOPB-om u odnosu na placebo kada se primjenjivao kao dodatak postojećoj osnovnoj terapiji (omjer hazarda [engl. hazard ratio, HR]: 0,89; 95% CI: 0,64; 1,23).
English: Do not use the Eklira Genuair if you notice that the pack is damaged or shows signs of tampering.
Croatian: Ovaj lijek ne smijete upotrijebiti ako primijetite da je pakiranje oštećeno ili su vidljivi znakovi neovlaštenog otvaranja.
English: Eklira Genuair 322 micrograms inhalation powder
Croatian: Eklira Genuair 322 mikrograma, prašak inhalata
English: If you forget to use Eklira Genuair
Croatian: Ako ste zaboravili primijeniti Eklira Genuair
English: Disease-Specific Health Status and Symptomatic Benefits Eklira Genuair provided clinically meaningful improvements in breathlessness (assessed using the Transition Dyspnoea Index [TDI]) and disease-specific health status (assessed using the St. George's Respiratory Questionnaire [SGRQ]).
Croatian: Transition Dyspnoea Index, TDI]) i zdravstvenog stanja povezanog s bolešću (procijenjenog pomoću St. George's respiratornog upitnika; eng. St. George's Respiratory Questionnaire [SGRQ]).
English: Acute intoxication by inadvertent medicinal product ingestion of aclidinium bromide is unlikely, due to its low oral bioavailability and the breath-actuated dosing mechanism of the Genuair inhaler.
Croatian: Akutno trovanje nehotičnim gutanjem aklidinijeva bromida malo je vjerojatno zbog njegove slabe oralne bioraspoloživosti i mehanizma doziranja udisanjem putem Genuair inhalatora.
English: How to store Eklira Genuair Contents of the pack and other information Instructions for Use
Croatian: Sadržaj pakiranja i druge informacije Upute za uporabu
English: In a 3-week crossover, randomised, placebo-controlled clinical study Eklira Genuair was associated with a statistically significant improvement in exercise endurance time in comparison to placebo of 58 seconds (95% CI=9-108; p=0.021; pre-treatment value: 486 seconds).
Croatian: U trotjednom, ukriženom, randomiziranom, placebom kontroliranom kliničkom ispitivanju, primjena Eklira Genuaira bila je povezana sa statistički značajnim poboljšanjem u vremenu izdržanog fizičkog napora od 58 sekundi, u usporedbi s placebom (95% CI=9-108; p=0,021; vrijednost prije početka liječenja: 486 sekundi).
English: In vitro studies have shown that aclidinium bromide or the metabolites of aclidinium bromide at the therapeutic dose are not expected to cause interactions with active substances that are substrates of P-glycoprotein (P-gp), or active substances metabolised by cytochrome P450 (CYP450) enzymes and esterases (see section 5.2).
Croatian: Ispitivanja in vitro su pokazala da se ne očekuju interakcije aklidinijeva bromida ili metabolita aklidinijeva bromida u terapijskim dozama s djelatnim tvarima koje su supstrati P-glikoproteina (P-gp) ili djelatnim tvarima koje se metaboliziraju putem citokroma P450 (CYP 450) i esterazama (vidjeti dio
English: The frequencies assigned to the undesirable effects listed below are based on crude incidence rates of adverse reactions (i.e. events attributed to Eklira Genuair) observed with Eklira Genuair 322 µg (636 patients) in the pooled analysis of one 6-month and two 3-month randomised, placebo-controlled clinical trials.
Croatian: Učestalost nuspojava u nastavku temelji se na grubim stopama incidencije (tj. događajima koji se pripisuju lijeku Eklira Genuair), zabilježenih s Eklira Genuair 322 µg (636 bolesnika) u združenoj analizi jednog 6-mjesečnog i dva 3-mjesečna randomizirana, placebom kontrolirana klinička ispitivanja.
English: EU/1/12/778/001 30 doses
Croatian: EU/1/12/778/001 30 doza
English: In addition, Eklira Genuair showed a statistically significant reduction of 35% in the rate of hospitalisations due to COPD exacerbations while on-treatment during the first year compared with placebo (RR 0.65; 95% CI 0.48 to 0.89; p=0.006).
Croatian: Uz to, Eklira Genuair omogućio je statistički značajno smanjenje stope hospitalizacija zbog egzacerbacija KOPB-a tijekom prve godine liječenja za 35% u usporedbi s placebom (RR: 0,65; 95% CI: 0,48 - 0,89; p=0,006).
English: EU/1/12/778/002 60 doses
Croatian: EU/1/12/778/002 60 doza
English: Patients treated with Eklira Genuair showed a statistically significant reduction of 22% compared to placebo (rate ratio [RR] 0.78; 95% CI 0.68 to 0.89; p<0.001).
Croatian: U bolesnika liječenih lijekom Eklira Genuair zabilježeno je statistički značajno smanjenje za 22% u odnosu na placebo (omjer stopa [engl. rate ratio, RR]: 0,78; 95% CI: 0,68 - 0,89; p < 0,001).
English: The median time on-study in the Eklira Genuair and placebo groups was approximately 1.4 and 1.3 years, respectively.
Croatian: Medijan trajanja sudjelovanja u ispitivanju iznosio je približno 1,4 godine u skupini liječenoj lijekom Eklira Genuair te 1,3 godine u skupini koja je primala placebo.
English: The median time on-treatment in the Eklira Genuair and placebo groups was 1.1 and 1 year, respectively.
Croatian: Medijan trajanja liječenja iznosio je 1,1 godinu u skupini liječenoj lijekom Eklira Genuair, a 1 godinu u onoj koja je primala placebo.
English: In addition, no clinically significant effects of Eklira Genuair on cardiac rhythm were observed on 24-hour Holter monitoring after 3 months treatment of 336 patients (of whom 164 received Eklira Genuair 322 µg twice daily).
Croatian: Osim toga, 24-satnim Holter motrenjem nakon 3 mjeseca liječenja 336 bolesnika (od kojih je 164 primalo Eklira Genuair od 322 µg dvaput dnevno), nisu zabilježeni značajni učinci lijeka Eklira Genuair na srčani ritam.
English: How to store Eklira Genuair
Croatian: Kako čuvati Eklira Genuair
English: Following inhalation of 200 µg and 400 µg of aclidinium bromide by healthy subjects or COPD patients, the urinary excretion of unchanged aclidinium was very low at about 0.1% of the administered dose, indicating that renal clearance plays a minor role in the total aclidinium clearance from plasma.
Croatian: izlučivanje nepromijenjenog aklidinija mokraćom bilo je vrlo nisko, tj. oko 0,1% primijenjene doze, ukazujući da bubrežni klirens ima malu ulogu u ukupnom klirensu aklidinija iz plazme.
English: How to use Eklira Genuair
Croatian: Kako primjenjivati Eklira Genuair
English: Eklira Genuair 322 micrograms inhalation powder aclidinium (aclidinium bromide)
Croatian: Eklira Genuair 322 mikrograma, prašak inhalata aklidinij (aklidinijev bromid)
English: What Eklira Genuair is used for
Croatian: Za što se koristi Eklira Genuair
English: Eklira Genuair 322 mcg inhalation powder aclidinium (aclidinium bromide) Inhalation use
Croatian: Eklira Genuair od 322 µg, prašak inhalata aklidinij (aklidinijev bromid)
English: Česká republika AstraZeneca Czech Republic s.r.o.
Croatian: United Kingdom AstraZeneca UK Ltd
English: Date of first authorisation: 24.05.2017
Croatian: Datum prvog odobrenja: 24.05.2017
English: Adjuvant: Carbomer 1 mg.
Croatian: Adjuvans: karbomer 1 mg.
English: Adjuvant: Carbomer
Croatian: Adjuvans: Karbomer
English: Pharmacotherapeutic group: Immunologicals for suidae, inactivated viral vaccines for pigs ATCvet code: QI09AA07
Croatian: Farmakoterapijska grupa: Imunološki pripravci za suidae, inaktivirano virusno cjepivo za svinje ATCvet kod: QI09AA07
English: Store and transport refrigerated (2 C-8 C).
Croatian: Čuvati i prevoziti na hladnom (2 C-8 C).
English: THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable
Croatian: 13. RIJEČI “SAMO ZA PRIMJENU NA ŽIVOTINJAMA” I UVJETI ILI OGRANIČENJA U POGLEDU OPSKRBE I PRIMJENE,
English: The active substance being a principle of biological origin intended to produce active immunity is not in the scope of Regulation (EC) 470/2009.
Croatian: Djelatna tvar se sastoji od tvari biološkog porijekla, koje su namijenjene za stvaranje aktivne imunosti, na koje se ne primjenjuju odredbe Uredbe (EK) br. 470/2009.
English: Do not mix with any other veterinary medicinal product, except with Ingelvac MycoFLEX (not for use in pregnant or lactating pigs).
Croatian: Ne miješati s bilo kojim drugim veterinarsko-medicinskim proizvodom, osim cjepivom Ingelvac MycoFLEX (ne primjenjivati kod gravidnih ili svinja u laktaciji).
English: Carbomer Sodium chloride Water for injections
Croatian: Natrijev klorid Voda za injekcije
English: Any unused mixture or waste material should be disposed according to the instructions given in section 6.6.
Croatian: Neiskorištenu mješavinu i otpadne materijale treba zbrinuti u skladu s uputama navedenima u odjeljku 6.6.
English: Do not use this veterinary medicinal product after the expiry date which is stated on the carton and the bottle after EXP.
Croatian: Ne koristiti veterinarsko-medicinski proizvod poslije isteka roka valjanosti naznačenog na kutiji i bočici poslije (EXP).
English: Ingelvac PCV FLEX suspension for injection for pigs
Croatian: Ingelvac PCV FLEX suspenzija za injekciju za svinje
English: No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the product mentioned above.
Croatian: Ne postoje dostupni podaci o neškodljivosti i djelotvornosti ovog cjepiva kada se primjenjuje s bilo kojim drugim veterinarsko-medicinskim proizvodom osim onim koji je naveden ranije.
English: Overdose (symptoms, emergency procedures, antidotes) Following the administration of a 4-fold overdose of vaccine no adverse reactions other than those described under section “Adverse reactions” have been observed.
Croatian: Predoziranje (simptomi, hitni postupci, antidoti) Nakon predoziranja četverostrukom dozom cjepiva nisu primijećene druge nuspojave osim onih opisanih u dijelu Nuspojave.
English: Each vial is closed with a chlorobutyl stopper and lacquered aluminium seal.
Croatian: Svaka bočica je zatvorena s čepom od klorobutila i lakiranim aluminijskim poklopcem.
English: When mixed with Ingelvac MycoFLEX the following recommendations should be followed:
Croatian: Prilikom miješanja s Ingelvac MycoFLEX treba se pridržavati sljedećih preporuka:
English: If needed, gently press the vaccine bottle of Ingelvac PCV FLEX to facilitate the transfer.
Croatian: Ako je potrebno, bočicu s cjepivom Ingelvac PCV FLEX lagano stisnite da započne prijenos.
English: • Use the same volumes of Ingelvac PCV FLEX and Ingelvac MycoFLEX.
Croatian: • koristite iste količine cjepiva Ingelvac PCV FLEX i Ingelvac MycoFLEX.
English: For active immunisation of pigs with no PCV2 maternally derived antibodies from the age of 2 weeks against porcine circovirus type 2 (PCV2).
Croatian: Za aktivnu imunizaciju svinja bez PCV2 protutijela, dobivenih od majke, starijih od 2 tjedna protiv cirkovirusa svinja tipa 2 (PCV2).
English: To ensure correct mixing follow the steps as described below: Connect one end of the transfer needle to the vaccine bottle of Ingelvac MycoFLEX.
Croatian: Da bi osigurali ispravno miješanje cjepiva treba postupati po sljedećim „koracima“: Spojite jedan kraj igle za prijenos cjepiva s bočicom Ingelvac MycoFLEX.
English: Safety and efficacy data are available which demonstrate that this vaccine can be mixed with Ingelvac MycoFLEX and administered at one injection site.
Croatian: Podaci o neškodljivosti i djelotvornosti su dostupni i pokazuju da se ovo cjepivo može pomiješati i primijeniti pomiješano s cjepivom Ingelvac MycoFLEX na isto injekcijsko mjesto.
English: To ensure appropriate mixing of the vaccines, gently shake the vaccine bottle of Ingelvac MycoFLEX until the mixture is of uniform orange to reddish colour.
Croatian: Kako bi bili sigurni da su cjepiva odgovarajuće pomiješana bočicu cjepiva Ingelvac MycoFLEX treba nježno protresti sve dok mješavina ne postane jednoliko narančasto- crvenkasta.
English: This vaccine is designed to stimulate the development of an active immune response to porcine circovirus type 2.
Croatian: Ovo cjepivo je napravljeno da potakne razvoj aktivnog imuniteta na cirkovirus svinja tip 2.
English: Any unused mixture or waste material should be disposed according with local requirements.
Croatian: Neiskorištenu mješavinu i otpadne materijale treba zbrinuti u skladu sa lokalnim propisima.
English: The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reactions) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
Croatian: Učestalost nuspojava je određena sukladno sljedećim pravilima: - vrlo česte (više od 1 na 10 tretiranih životinja pokazuju nuspojavue) - česte (više od 1 ali manje od 10 životinja na 100 tretiranih životinja) - manje česte (više od 1 ali manje od 10 životinja na 1.000 tretiranih životinja) - rijetke (više od 1 ali manje od 10 životinja na 10.000 tretiranih životinja) - vrlo rijetke (manje od 1 životinje na 10.000 tretiranih životinja, uključujući izolirane slučajeve).
English: A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case-by-case basis.
Croatian: Stoga se odluka o primjeni ovog cjepiva prije, odnosno poslije primjene bilo kojeg drugog veterinarskomedicinskog proizvoda, mora donositi od slučaja do slučaja.
English: The PSURs for Ingelvac PCV FLEX shall be submitted at the same frequency as for Ingelvac CircoFLEX.
Croatian: Periodička izvješća o neškodljivosti (PSUR) za Ingelvac PCV FLEX treba podnositi s istom učestalosti kao i za Ingelvac CircoFLEX.
English: Under experimental challenge conditions in which only seronegative animals were included, it was demonstrated that vaccination reduces mortality, clinical signs and lesions in lymphoid tissues associated with PCV2 related disease (PCVD).
Croatian: Pri uvjetima eksperimentalnog izazova u koji su bile uključene samo seronegativne životinje, dokazano je da cijepljenje smanjuje mortalitet, klinički znakovi i lezije limfnog tkiva povezane s bolešću (PCVD) koju izaziva PCV2.
English: In addition, vaccination has been shown to reduce PCV2 nasal shedding, viral load in blood and lymphoid tissues, and duration of viraemia.
Croatian: Uz to se pokazalo da cijepljenje smanjuje izlučivanje PCV2 iz nosa, količinu virusa u krvi i limfnom tkivu te trajanje viremije.
English: One dose (1 ml) contains: Porcine circovirus type 2 ORF2 protein Carbomer 1 mg.
Croatian: Jedna doza (1 ml) sadrži: cirkovirus svinja tip 2, bjelančevina ORF2 Karbomer 1 mg.
English: - After the transfer of the full content of Ingelvac PCV FLEX, disconnect and discard transfer needle and empty vaccine bottle of Ingelvac PCV FLEX.
Croatian: - Nakon što se prenese cijeli sadržaj cjepiva Ingelvac PCV FLEX, odvoji se igla za prijenos i odloži zajedno s praznom bočicom cjepiva Ingelvac PCV FLEX.
English: One dose (1 ml): Porcine circovirus type 2 ORF2 protein Carbomer
Croatian: Jedna doza (1 ml): cirkovirus svinja tip 2, bjelančevina ORF2 Karbomer
English: 10 ml, 50 ml bottle
Croatian: 10 ml, 50 ml bočica
English: D. CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
Croatian: OSTALI UVJETI I ZAHTJEVI ODOBRENJA ZA STAVLJANJE U PROMET
English: 100 ml, 250 ml bottle
Croatian: 100 ml, 250 ml bočica
English: Porcine circovirus type 2 ORF2 protein: RP* 1.0-3.75 * Relative potency (ELISA test) by comparison with a reference vaccine.
Croatian: Cirkovirus svinja tip 2, bjelančevina ORF2 * Relativna potencija (ELISA test) u usporedbi s referentnim cjepivom.
English: - Transfer the Ingelvac PCV FLEX vaccine into the vaccine bottle of Ingelvac MycoFLEX.
Croatian: - Prebacite cjepivo Ingelvac PCV FLEX u bočicu s cjepivom Ingelvac MycoFLEX.
English: Pack sizes of 1 or 12 bottles of 10 ml (10 doses), 50 ml (50 doses), 100 ml (100 doses) or 250 ml (250 doses).
Croatian: Pakiranje sadržava 1 ili 12 bočica od 10 ml (10 doza), 50 ml (50 doza), 100 ml (100 doza) ili 250 ml (250 doza).
English: Name and address of the manufacturers responsible for batch release Boehringer Ingelheim Vetmedica GmbH 55216 Ingelheim/Rhein
Croatian: Naziv i adresa proizvođača odgovornog za puštanje serije u promet Boehringer Ingelheim Vetmedica GmbH 55216 Ingelheim/Rhein
English: - Connect the opposite end of the transfer needle to the vaccine bottle of Ingelvac PCV FLEX.
Croatian: - Spojite suprotni kraj igle za prijenos cjepiva s bočicom Ingelvac PCV FLEX.
English: Pack sizes of 1 or 12 high density polyethylene bottles of 10 ml (10 doses), 50 ml (50 doses), 100 ml (100 doses) or 250 ml (250 doses).
Croatian: Pakiranje sadržava 1 ili 12 bočica, od polietilena visoke gustoće, od 10 ml (10 doza), 50 ml (50 doza), 100 ml (100 doza) ili 250 ml (250 doza).
English: Carton of 10 ml, 50 ml, 100 ml, 250 ml bottles
Croatian: Kutija s bocama 10 ml, 50 ml, 100 ml, 250 ml
English: The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reactions) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated)
Croatian: Učestalost nuspojava je određena sukladno sljedećim pravilima: - vrlo česte (više od 1 na 10 tretiranih životinja pokazuju nuspojavue) - česte (više od 1 ali manje od 10 životinja na 100 tretiranih životinja)
English: - very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
Croatian: - manje česte (više od 1 ali manje od 10 životinja na 1.000 tretiranih životinja) - rijetke (više od 1 ali manje od 10 životinja na 10.000 tretiranih životinja) - vrlo rijetke (manje od 1 životinje na 10.000 tretiranih životinja, uključujući izolirane slučajeve).
English: 6.1 List of excipients
Croatian: 6.1 Popis pomoćnih tvari Karbomer
English: Avoid multiple broaching.
Croatian: Izbjegavajte višekratno probadanje čepa na bočici.
English: PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE
Croatian: OSNOVNI PODACI KOJI SE MORAJU NALAZITI NA UNUTARNJEM PAKOVANJU
English: Following the administration of a 4-fold overdose of vaccine no adverse reactions other than those described under section 4.6 have been observed.
Croatian: 4.10 Predoziranje (simptomi, hitni postupci, antidoti), ako je nužno Nakon predoziranja četverostrukom dozom cjepiva nisu primijećene druge nuspojave osim onih opisanih u dijelu 4.6.
English: Name and address of the manufacturer of the biological active substance Boehringer Ingelheim Vetmedica Inc.
Croatian: Nositelj odobrenja za stavljanje u promet i proizvođač odgovoran za puštanje proizvodne serije: Boehringer Ingelheim Vetmedica GmbH
English: 1 tube Not applicable
Croatian: 1 tuba nije primjenjivo
English: Cats Transdermal use Tube (Alu) 5 g
Croatian: 20 mg/g transdermalna mast mačke primjena kroz kožu tuba (aluminijska)
English: Invented name
Croatian: Novoizuml jeno ime
English: Content Package size
Croatian: Sadržaj Veličina pakiranj a
English: Immediate packaging
Croatian: Put primjene Unutarnje pakiranje
English: If you or your daughter:
Croatian: Ako ste Vi ili Vaša kći:
English: This leaflet was last revised in [{MM/YYYY}].
Croatian: Ova uputa je zadnji puta revidirana u [{MM/GGGG}].
English: Other serious reactions
Croatian: Ostale ozbiljne reakcije
English: • The first injection will be given at the chosen or scheduled date.
Croatian: • Prva injekcija primijenit će se na odabran ili dogovoren datum.
English: 2.5 Long-term protection
Croatian: 2.5 Dugoročna zaštita
English: Additional side effects in adults:
Croatian: Dodatne nuspojave u odraslih:
English: Occasionally dengue can be severe enough for you to have to go to hospital and in rare cases it can cause death.
Croatian: Ponekad denga može biti dovoljno teška da zbog nje morate ići u bolnicu, a u rijetkim slučajevima može biti i smrtonosna.
English: You or your child will receive 3 injections of 0.5 mL - one every 6 months.
Croatian: Vi ili Vaše dijete primit ćete 3 injekcije od 0,5 ml - po jednu svakih 6 mjeseci.
English: Children and adults 9 to 45 years of age
Croatian: Djeca i odrasli u dobi od 9 do 45 godina
English: The following side effects occurred during studies in children, young people and adults.
Croatian: Sljedeće su se nuspojave javile tijekom ispitivanja provedenih u djece, mladih osoba i odraslih.
English: You can also have dengue but show no symptoms (called "asymptomatic").
Croatian: Možete imati dengu, ali ne pokazivati simptome (što se zove „asimptomatskom”
English: The recommended size of the needle to be used is 23G or 25G.
Croatian: Preporučuje se koristiti igle veličine 23G ili 25G.
English: Your doctor will carefully consider the risks and benefits of vaccination.
Croatian: Vaš će liječnik pažljivo razmotriti rizike i koristi cijepljenja.
English: This includes using insect repellents, wearing protective clothing, and using mosquito nets.
Croatian: To uključuje uporabu repelenata protiv insekata, nošenje zaštitne odjeće i korištenje mreže za zaštitu od komaraca.
English: • This vaccine has been prescribed for you or your child only.
Croatian: • Ovo je cjepivo propisano Vama ili Vašem djetetu.
English: Most of the subjects were 9 to 17 years of age (n= 2810).
Croatian: Većina ispitanika bila je u dobi od 9 do 17 godina (n = 2810).
English: This may be due to a genetic defect or HIV infection.
Croatian: To može biti posljedica genskog poremećaja ili HIV infekcije
English: CYD28: Low endemic country
Croatian: CYD28: zemlja niske endemičnosti
English: The suspension should be visually inspected prior to administration.
Croatian: Suspenziju treba vizualno pregledati prije primjene.
English: • There is any suspicion that the partially used vial has been contaminated.
Croatian: • ako postoji bilo kakva sumnja da je djelomično iskorištena bočica kontaminirana
English: Therefore, protection is expected in adults in endemics areas although the actual magnitude of efficacy relative to that observed in children and adolescents is unknown.
Croatian: Stoga se u odraslih osoba u endemskim područjima očekuje zaštita, premda stvarni razmjer djelotvornosti u odnosu na onaj opažen u djece i adolescenata nije poznat.
English: Control group
Croatian: Kontrolna skupina